- Trials with a EudraCT protocol (127)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
127 result(s) found for: Rapid diagnostic test.
Displaying page 1 of 7.
EudraCT Number: 2006-003519-33 | Sponsor Protocol Number: D1443L00003 | Start Date*: 2007-01-25 |
Sponsor Name:AstraZeneca UK Limited | ||
Full Title: RAPID - An Open-Label, Randomised, Multicentre Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immedicate Release), over 14 days, in Acute Schizophrenia / Schizoaffecti... | ||
Medical condition: Acute Schizophrenia and Schizoaffective Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-006426-26 | Sponsor Protocol Number: D1443L00009 | Start Date*: 2007-01-17 |
Sponsor Name:AstraZeneca AB | ||
Full Title: FAST – A randomised, open-label, parallel, multicentre Phase IIIb Study to evaluate the Efficacy and Safety of Quetiapine IR titrared over 4 Days in Patients with Acute Psychosis (Rapid versus Conv... | ||
Medical condition: Patients requiring treatment, as judged by the Investigator, for an acute episode of schizophrenia, schizoaffective disorder, psychosis NOS or bipolar mania (according to DSM-IV criteria). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-002468-24 | Sponsor Protocol Number: NV20234 | Start Date*: 2008-02-13 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza | |||||||||||||
Medical condition: To investigate the optimal therapy for influenza in immunocompromised transplant recipients. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) BE (Completed) HU (Completed) LT (Completed) CZ (Completed) EE (Completed) IT (Completed) GR (Prematurely Ended) BG (Completed) LV (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001369-25 | Sponsor Protocol Number: HPT30/J/17 | Start Date*: 2018-03-19 |
Sponsor Name:INFAI Institut für biomedizinische Analytik und NMR Imaging GmbH | ||
Full Title: The Sensitivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal with 13C-Urea Breath Test in Helicobacter Pylori Positive and Negative Patients with Dyspepsia and GERD T... | ||
Medical condition: Diagnosis of Helicobacter pylori infection for patients taking proton pump inhibitors (PPI) with one day break of medication instead of two weeks prior to the test | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000316-31 | Sponsor Protocol Number: HIDR-0721/COV | Start Date*: 2021-07-15 |
Sponsor Name:FAES FARMA S.A. | ||
Full Title: Multicenter, double-blind, randomized clinical trial to evaluate the efficacy of calcifediol soft capsules versus placebo in reducing hospital admissions in patients with a positive diagnostic test... | ||
Medical condition: SARS-CoV-2 coronavirus infection (COVID-19). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-003642-93 | Sponsor Protocol Number: 53718678RSV2002 | Start Date*: 2018-12-05 | ||||||||||||||||
Sponsor Name:Janssen Sciences Ireland UC | ||||||||||||||||||
Full Title: A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses o... | ||||||||||||||||||
Medical condition: Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Prematurely Ended) HU (Completed) SE (Completed) FR (Completed) DE (Prematurely Ended) PL (Completed) BG (Completed) Outside EU/EEA IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002190-10 | Sponsor Protocol Number: UCDCRC/20/03 | Start Date*: 2021-02-05 |
Sponsor Name:University College Dublin | ||
Full Title: Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) | ||
Medical condition: Coagulopathy of COVID-19 appears to afflict approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by ele... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002204-24 | Sponsor Protocol Number: 1160.203 | Start Date*: 2014-12-17 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: REVERSAL OF ANTICOAGULANT EFFECT OF DABIGATRAN® BY PROTHROMBIN COMPLEX CONCENTRATE (BERIPLEX®) ASSESSED WITH A NOVEL METHOD OF BLOOD LOSS MEASUREMENT | ||
Medical condition: Healthy male volunteers. Study assessing the effect of a single 50IU/Kg dose of Beriplex on the anticoagulant effect of Dabigatran. This is of interest when rapid reversal of its effect is mandate... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002578-29 | Sponsor Protocol Number: 2019-5787 | Start Date*: 2020-01-21 |
Sponsor Name:Radboudumc | ||
Full Title: Functional Improvement of non-infarcT relaTed coronary artery stenosis by Extensive LDL-C Reduction with a PCSK9 Antibody. | ||
Medical condition: Coronary artery disease (CAD) Optimal treatment approach for bystander lesions in non-infarct related arteries (non-IRA’s) has not been well established. Multiple RCT’s favor preventive PCI over ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005451-20 | Sponsor Protocol Number: MMI_2020_35 | Start Date*: 2021-06-03 |
Sponsor Name:Fondation A. de Rothschild Hospital | ||
Full Title: REperfusion with P2Y12 inhibitors in addition to mEchanical thRombectomy for perFUsion imaging selected acute Stroke patiEnts : a multicentric randomized controlled trial | ||
Medical condition: patients with a clinical diagnosis of AIS consecutive to LVO between 0 and 24 hours of symptom onset and selected by perfusion imaging | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003571-56 | Sponsor Protocol Number: APX001-201 | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:Amplyx Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non-Neutropenic Patients with Candidemia, with or without Invasive Candidiasis, Inclusive of Patients with Suspected Resistance ... | |||||||||||||
Medical condition: Treatment of non-neutropenic subjects with candidemia – inclusive of those subjects with suspected or confirmed antifungal-resistant candidemia with or without invasive candidiasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000919-26 | Sponsor Protocol Number: IVH05 | Start Date*: 2005-07-29 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust [...] | ||
Full Title: Phase II, randomized, pharmokinetic, dose finding, and dose frequency determination using rt-PA in intraventricular hemorrhage | ||
Medical condition: Intracerebral haemorrhage with intraventricular extension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004758-33 | Sponsor Protocol Number: Rapid-study | Start Date*: 2015-09-08 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Randomized Assessment of patients with clinically suspected Prostate cancer after multiparametric metabolic hybrid Imaging to evaluate its potential clinical Domain: A prospective, randomized, mult... | |||||||||||||
Medical condition: Clinical suspected prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000223-42 | Sponsor Protocol Number: ZiSe | Start Date*: 2005-10-31 |
Sponsor Name:University Hospital Hamburg-Eppendorf, Psychiatry | ||
Full Title: Effects of ziprasidone vs. placebo during the first four weeks of eight weeks sertraline treatment in patients with posttraumatic stress disorder (PTSD) | ||
Medical condition: Post-traumatic Stress Disorder (PTSD) according to DSM-IV criteria | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003072-19 | Sponsor Protocol Number: PCSA/remi | Start Date*: 2007-06-20 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: Remifentanil administered by controlled tecnique PCSA by patients versus Meperidina administered by physician for diagnostic and operative endoscopic procedures. | |||||||||||||
Medical condition: patients undergoing diagnostic or operative procedures of endoscopic type with planned sadation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001588-63 | Sponsor Protocol Number: 200925 | Start Date*: 2020-10-23 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neon... | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003252-24 | Sponsor Protocol Number: 53718678RSV2004 | Start Date*: 2018-01-16 | |||||||||||
Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
Full Title: A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ- 53718678 at Two Dose Le... | |||||||||||||
Medical condition: Respiratory Syncytial Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) SE (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005122-45 | Sponsor Protocol Number: D1441L00032 | Start Date*: 2005-05-18 |
Sponsor Name:AstraZeneca GmbH | ||
Full Title: RACE : Rapid Dose Escalation of Quetiapine versus Conventional Escalation in the Treatment of Patients with Acute Schizophrenia – a Multicentre, Double-blind, Parallel group, Randomized Study | ||
Medical condition: Patients hospitalised with a DSM-IV diagnosis of schizophrenia showing acute agitation and psychosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002014-39 | Sponsor Protocol Number: RTB-101-205 | Start Date*: 2019-08-30 |
Sponsor Name:resTORbio, Inc. | ||
Full Title: A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly | ||
Medical condition: Clinically Symptomatic Respiratory Illness in the Elderly | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001489-17 | Sponsor Protocol Number: SIOPENRNET003 | Start Date*: 2006-11-17 |
Sponsor Name:St. Anna Kinderkrebsforschung e.V. | ||
Full Title: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) | ||
Medical condition: High Risk Neuroblastoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) DK (Restarted) IT (Completed) IE (Completed) HU (Completed) FI (Completed) SI (Completed) PL (Completed) GR (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
